Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561897PMC
http://dx.doi.org/10.3389/fpsyg.2022.1020222DOI Listing

Publication Analysis

Top Keywords

commentary psychedelics
4
psychedelics psychotherapy
4
psychotherapy cognitive-behavioral
4
cognitive-behavioral approaches
4
approaches default
4
commentary
1
psychotherapy
1
cognitive-behavioral
1
approaches
1
default
1

Similar Publications

Dr. Jeffrey et al. Reply.

J Am Acad Child Adolesc Psychiatry

December 2024

UCLA Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, California; The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles, California.

We are writing in response to 2 Letters to the Editor, both of which discussed our commentary, entitled "Clinical Research Trials of Psychedelic-Assisted Therapy in Adolescents Aged 16 to 17 Years: Rationale Balanced With Caution." We appreciate the thoughtful responses to our commentary, and we invite further dialogue about this important subject. Both letters emphasized the importance in engaging in thoughtful research approaches to ensure the safety of individuals who are administered psychedelics.

View Article and Find Full Text PDF

We read with great interest the commentary by Jeffrey et al. entitled "Clinical Research Trials of Psychedelic-Assisted Therapy in Adolescents Aged 16 to 17 Years: Rationale Balanced With Caution." We appreciate the efforts of the authors, the scholarship of this commentary, and the advocacy for research initiatives with psychedelic therapeutics such as psilocybin, lysergic acid diethylamide, and 3,4-methylenedioxymethamphetamine.

View Article and Find Full Text PDF

We read with interest the Commentary by Jeffrey et al. encouraging clinical research using psychedelics for adolescents. Throughout their commentary, the authors operate under the general presupposition that psychedelics have demonstrated a favorable safety profile in adults, and that therefore teenagers approaching an adult level of neurodevelopment can likely be safely treated with appropriate safeguards.

View Article and Find Full Text PDF

Legal and Ethics Concerns of Psilocybin as Medicine.

J Am Acad Psychiatry Law

December 2024

Dr. Schonholz is a psychiatry resident, Mount Sinai Hospital, New York, NY. Dr. Appel is a Professor of Psychiatry and Medical Education, Icahn School of Medicine at Mount Sinai, New York, NY. Dr. Bursztajn is an Associate Professor of Psychiatry and cofounder, Program in Psychiatry and the Law, Beth Israel Deaconess Medical Center Psychiatry, Harvard Medical School, Boston, MA and President, American Unit of the International Chair in Bioethics, Cambridge, MA. Dr. Nair is in private practice, Clinical & Forensic Neuropsychiatry/Brain Injury Medicine, Seal Beach, CA. Dr. MacIntyre is a Health Sciences Clinical Assistant Professor, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA.

Preliminary research shows the psychedelic psilocybin to be a promising potential treatment for psychiatric illnesses. Recent U.S.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!